check_circleStudy Completed
Atrial Fibrillation
Bayer Identifier:
18733
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Real-world dosing patterns of rivaroxaban in the United States
Trial purpose
The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.
The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).
The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).
Key Participants Requirements
Sex
BothAge
18 - N/A YearsTrial summary
Enrollment Goal
12507Trial Dates
February 2016 - March 2016Phase
N/ACould I Receive a placebo
NoProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | New York, United States |
Primary Outcome
- Number of NVAF patients receiving 20 mg Rivaroxabandate_rangeTime Frame:At baselineenhanced_encryptionNoSafety Issue:
- Number of NVAF patients receiving 15 mg Rivaroxabandate_rangeTime Frame:At baseline
Secondary Outcome
- Baseline renal functiondate_rangeTime Frame:At baseline
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A